Abstract

Abstract Introduction Sexual dysfunction (SD) is known to be associated with selective serotonin reuptake inhibitors (SSRIs). Objective To determine the effect of different SSRIs on SD development in males, particularly erectile dysfunction (ED), a systematic review was conducted according to PRISMA guidelines. Methods Literature, in English language, published between January 2009 and September 2019 was searched using two electronic databases, PubMed and EMBASE. Studies were screened according to the predefined inclusion-exclusion criteria. The bibliographies of the included articles were screened to identify any relevant articles. Results A total of ten articles were included (8/811 articles searched; two from bibliographies of eight included articles). Treatment-emergent SD, particularly ED was observed in male participants, although the ED incidence was low, less than 2%. SSRIs – fluoxetine, escitalopram, and citalopram – showed a higher risk of ED than other SSRIs. Conclusions The findings indicated a positive association between SSRIs and SD. However, evidence supporting a strong link between SSRIs and ED was insufficient. Disclosure Any of the authors act as a consultant, employee or shareholder of an industry for: jouf university, Saudi arabia.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.